2 weeks Ago By ABMN Staff
Cerity Partners LLC lifted its holdings in shares of Genmab A/S ( NASDAQ:GMAB – Free Report ) by 6.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 51,264 shares of the company’s stock after buying an additional 3,261 shares during the quarter.
Cerity Partners LLC’s holdings in Genmab A/S were worth $1,070,000 at the end of the most recent quarter. Several other institutional investors and hedge funds also recently bought and sold shares of GMAB. Brandywine Global Investment Management LLC purchased a new stake in shares of Genmab A/S during the fourth quarter worth $33,804,000.
Russell Investments Group Ltd. grew its holdings in Genmab A/S by 18,959.1% during the 4th quarter.
Russell Investments Group Ltd. now owns 510,784 shares of the company’s stock valued at $10,660,000 after buying an additional 508,104 shares in the last quarter. JPMorgan Chase & Co.
increased its position in shares of Genmab A/S by 3,049.3% during the fourth quarter. JPMorgan Chase & Co.
now owns 407,613 shares of the company’s stock valued at $8,507,000 after buying an additional 394,670 shares during the period. Trexquant Investment LP grew its stake in Genmab A/S by 495.1% during the fourth quarter.
Trexquant Investment LP now owns 379,936 shares of the company’s stock valued at $7,929,000 after acquiring an additional 316,089 shares in the last quarter. Finally, LPL Financial LLC increased its holdings in Genmab A/S by 3.3% during the 4th quarter.
LPL Financial LLC now owns 195,436 shares of the company’s stock worth $4,079,000 after acquiring an additional 6,288 shares during the period. 7.07% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades GMAB has been the topic of several research analyst reports. Leerink Partnrs raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. Leerink Partners upgraded Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.
00 price target for the company in a research report on Thursday, February 13th. William Blair upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 11th. Sanford C.
Bernstein cut shares of Genmab A/S from a “market perform” rating to an “underperform” rating in a research note on Tuesday, April 1st. Finally, HC Wainwright restated a “buy” rating and set a $37.00 price objective (down previously from $50.
00) on shares of Genmab A/S in a research report on Wednesday, April 9th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.
com, the company has a consensus rating of “Moderate Buy” and an average target price of $39.17. Genmab A/S Trading Up 2.
5 % GMAB opened at $20.04 on Friday. The company has a market cap of $13.
26 billion, a P/E ratio of 11.52, a P/E/G ratio of 2.65 and a beta of 1.
07. Genmab A/S has a 12 month low of $17.24 and a 12 month high of $30.
41. The business’s 50-day moving average price is $20.54 and its 200-day moving average price is $21.
17. Genmab A/S ( NASDAQ:GMAB – Get Free Report ) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.
57 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.29.
Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%.
Equities research analysts forecast that Genmab A/S will post 1.45 earnings per share for the current fiscal year. Genmab A/S Company Profile ( Free Report ) Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.
The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Featured Articles Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter .
.
